Table 2.

Effects of RGS treatment versus control on clinical scales within and between groups for the post treatment assessment at week 3 and the long-term follow up at week 12.

Assessment	RGS (n=17)			Control (n=18)				Between Groups		Effect size
	Improvement, mean (SD)		P	Improvement, mean (SD)		P		P		Cohen d
End (Week 3)
UE-FMa	0.35 (1.62)		.43	1.22 (3.84)		.15		.33		−0.30
CAHAIb	1.53 (2.4)		.01	−0.67 (6.01)		.90		.05		0.48
Barthel	0.00 (1.87)		>.99	1.00 (2.87)		.25		.44		−0.41
MRCpc	0.06 (0.24)		>.99	0.11 (0.32)		.50		.61		−0.17
MRCdd	0.06 (0.43)		>.99	0.11 (0.47)		.63		.74		−0.12
Aspe	0.00 (0.35)		>.99	0.06 (0.24)		>.99		.32		0.40
Asdf	0.12 (0.33)		.50	0.00 (0.34)		>.99		.32		0.36
Grip force	0.41 (1.78)		.89	0.38 (2.65)		.47		.57		0.01
Hamilton	0.88 (2.45)		.16	0.67 (1.57)		.13		.66		0.10
VAS-Sg	0.41 (1.81)		.05	−0.28 (1.90)		.69		.63		0.37
Follow-up (Week 12)
UE-FM	−0.18 (3.50)		.82	1.39 (3.63)		.11		.21		0.34
CAHAI	−0.06 (6.51)		.74	0.44 (5.46)		.67		.61		−0.08
Barthel	−3.30 (8.09)		.29	−0.11 (3.98)		.92		.74		−0.50
MRCp	−0.12 (0.78)		>.99	0.28 (0.46)		.06		.06		−0.62
MRCd	0.29 (0.77)		.25	0.17 (0.62)		45		.98		−0.17
Asp	0.06 (0.65)		>.99	0.00 (0.34)		>.99		>.99		−0.12
Asdf	0.29 (0.59)		.13	0.00 (0.00)		>.99		.03		0.70
Grip force	0.21 (1.45)		.73	0.23 (3.02)		.92		.93		−0.01
Hamilton	0.35 (2.34)		.70	1.11 (3.53)		.42		.93		−0.25
VAS-S	0.12 (2.06)		.92	0.78 (3.08)		.38		.27		−0.25

^aUE-FM: The upper extremity Fugl-Meyer Assessment.

^bCAHAI: Chedoke Arm and Hand Activity Inventory (version CAHAI-13).

^cMRCp: Medical Research Council for proximal muscles.

^dMRCd: Medical Research Council for distal muscles.

^eAsp: Ashworth Scale for proximal muscles.

^fAsd: Ashworth Scale for distal muscles.

^gVAS-S: Visual Analog Scale for Shoulder Pain.